Sodium Phenylbutyrate Is Estimated To Witness High Growth Owing To Opportunity To Treat Urea Cycle Disorders

Sodium Phenylbutyrate Sodium phenylbutyrate is a medication that alters the breakdown of waste products in the liver. It is used to treat urea cycle disorders, primarily involving deficiencies or defects of the liver enzyme that removes ammonia from the blood. It works by enabling alternative pathways for the removal of nitrogen from the blood in patients with urea cycle disorders, which reduces ammonia accumulation. The global sodium phenylbutyrate market is estimated to be valued at US$ 1.92 Billion in 2023 and is expected to exhibit a CAGR of 4.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Opportunity: The opportunity to treat urea cycle disorders presents a major market opportunity for sodium phenylbutyrate. Urea cycle disorders are a group of rare, inherited metabolic disorders caused by genetic defects that affect the urea cycle, which is crucial for removing ammonia from the blood. Left untreated,...